HAP Trading’s Lifecore Biomedical LFCR Stock Holding History

HAP Trading’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-939,300	Closed	-$2.56M	–	1169
2023 Q2	$2.56M	Buy	+939,300	New	+$5.74M	0.45%	48

Other funds holding LFCR

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return

GRIM

Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

325 Capital New York $274M AUM 49.96% 1-Year Est. Return

CSC

Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VWA

Visionary Wealth Advisors O'fallon, Illinois $2.26B AUM 19.48% 1-Year Est. Return

HAP Trading's LFCR Position: Q4 2023 in Review

HAP Trading sold out of Lifecore Biomedical (LFCR) in Q4 2023, closing a stake of 163,773 shares — an estimated $1.24M sold.

HAP Trading first reported a position in LFCR in Q3 2023 and held it in 1 quarter. The position peaked at $1.24M in Q3 2023. 78 funds tracked by Wall St. Rank hold LFCR as of Q4 2023.

HAP Trading reported no remaining Lifecore Biomedical position as of Q4 2023 after selling out during the quarter.
HAP Trading sold 163,773 Lifecore Biomedical shares in Q4 2023, an estimated $1.24M.
HAP Trading first reported a position in Lifecore Biomedical in Q3 2023 and held it in 1 quarter.
HAP Trading's Lifecore Biomedical position peaked at $1.24M in Q3 2023.
78 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q4 2023.

Based on HAP Trading's 13F filing for Q4 2023, filed 14 Feb 2024.